The clinical and diagnostic utility of S100B in preterm newborns

Laura D. Serpero, Francesca Pluchinotta, Diego Gazzolo

Research output: Contribution to journalArticle

Abstract

Preterm birth is still the most important cause of perinatal mortality and morbidity. Follow-up studies showed that the majority of neurological abnormalities during childhood are already present in the first week after birth. In this light, the knowledge of the timing of the insult and/or of the contributing factors is of utmost relevance in order to avoid adverse neurological outcome. Notwithstanding, the considerable advances in perinatal clinical care and monitoring, the early detection of cases at risk for brain damage is still a challenge because, when radiological pictures are still negative, brain damage may be already at a subclinical stage, with symptoms hidden by therapeutic strategies. Thus, it could be very relevant to measure quantitative parameters, such as neuroproteins, able to detect subclinical lesions at a stage when routine brain monitoring procedures are still silent.In the last decade, the assay of the brain-specific protein S100B in different biological fluids proved useful information on brain function and damage in the perinatal period.Therefore, the present study provides an overview of the most recent findings on S100B role as a reliable marker of brain development/damage in preterm high risk fetuses and newborns.

Original languageEnglish
Pages (from-to)193-198
Number of pages6
JournalClinica Chimica Acta
Volume444
DOIs
Publication statusPublished - Apr 5 2015

Keywords

  • Brain damage
  • Congenital heart diseases
  • Fetus
  • Hypoxia
  • Newborn
  • S100B

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'The clinical and diagnostic utility of S100B in preterm newborns'. Together they form a unique fingerprint.

  • Cite this